These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35446398)

  • 1. Insurance Delays in Initiation of Tumor Necrosis Factor Inhibitors in Children With Juvenile Idiopathic Arthritis.
    Roberts JE; Fan M; Son MBF
    JAMA Netw Open; 2022 Apr; 5(4):e228330. PubMed ID: 35446398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Variants and Therapeutic Response to Anti-TNF-α Agents in Juvenile Idiopathic Arthritis: An Updated Systematic Review and Meta-analysis.
    Pregnolato F; Chighizola CB; Giani T; Costi S; Marino A; Cimaz R
    J Clin Rheumatol; 2022 Oct; 28(7):374-378. PubMed ID: 35777854
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis).
    Agle LM; Rosenkranz M; Lehman TJ
    Expert Opin Investig Drugs; 2003 Jan; 12(1):19-28. PubMed ID: 12517251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refractory systemic juvenile idiopathic arthritis successfully treated with rapamycin.
    Concha S; Rey-Jurado E; Poli MC; Hoyos-Bachiloglu R; Borzutzky A
    Rheumatology (Oxford); 2021 Jul; 60(7):e250-e251. PubMed ID: 33547778
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.
    Dimopoulou D; Spyridis N; Vartzelis G; Tsolia MN; Maritsi DN
    Arthritis Rheumatol; 2022 Feb; 74(2):365-366. PubMed ID: 34492161
    [No Abstract]   [Full Text] [Related]  

  • 6. Rapid Resolution of Erosive Psoriatic Juvenile Idiopathic Arthritis With Anti-Tumor Necrosis Factor Therapy.
    Felix MD; Ostrov BE
    J Clin Rheumatol; 2021 Dec; 27(8S):S688-S689. PubMed ID: 33136694
    [No Abstract]   [Full Text] [Related]  

  • 7. The Effect of Tumor Necrosis Factor α Blockers on Growth Velocity in Juvenile Idiopathic Arthritis.
    Mrážik P; Vargová V; Košková E
    J Clin Rheumatol; 2015 Oct; 21(7):376-8. PubMed ID: 26398470
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching.
    Brunelli JB; Silva CA; Pasoto SG; Saa CGS; Kozu KT; Goldenstein-Schainberg C; Leon EP; Vendramini MBG; Fontoura N; Bonfa E; Aikawa NE
    Clin Rheumatol; 2020 Feb; 39(2):515-521. PubMed ID: 31707543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
    Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
    Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiologic Improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept.
    Tse SM; Laxer RM; Babyn PS; Doria AS
    J Rheumatol; 2006 Jun; 33(6):1186-8. PubMed ID: 16755667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy for juvenile spondyloarthritis: an overview of the available therapies.
    Marino A; De Souza M; Giani T; Cimaz R
    Expert Opin Pharmacother; 2020 Dec; 21(17):2161-2168. PubMed ID: 32726179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
    Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
    Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards therapeutic drug monitoring of TNF inhibitors for children with juvenile idiopathic arthritis: a scoping review.
    Verstegen RHJ; McMillan R; Feldman BM; Ito S; Laxer RM
    Rheumatology (Oxford); 2020 Feb; 59(2):386-397. PubMed ID: 31335941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA.
    Yue X; Huang B; Hincapie AL; Wigle PR; Li Y; Qiu T; Lovell DJ; Morgan EM; Guo JJ
    Rheumatology (Oxford); 2021 Sep; 60(9):4063-4073. PubMed ID: 34469569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
    Cummins C; Connock M; Fry-Smith A; Burls A
    Health Technol Assess; 2002; 6(17):1-43. PubMed ID: 12234456
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis.
    Weiss PF; Xiao R; Brandon TG; Pagnini I; Wright TB; Beukelman T; Morgan-DeWitt E; Feudtner C
    J Rheumatol; 2018 Jan; 45(1):107-114. PubMed ID: 28916542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Judicious use of biologicals in juvenile idiopathic arthritis.
    Zhao Y; Wallace C
    Curr Rheumatol Rep; 2014 Nov; 16(11):454. PubMed ID: 25218736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the treatment of juvenile idiopathic arthritis.
    Harris JG; Kessler EA; Verbsky JW
    Curr Allergy Asthma Rep; 2013 Aug; 13(4):337-46. PubMed ID: 23605168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor inhibitors and cancer in juvenile idiopathic arthritis: disentangling the web.
    Onel KB; Onel K
    Arthritis Rheum; 2012 Apr; 64(4):966-9. PubMed ID: 22327954
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor Necrosis Factor-α Inhibition Before and After Rituximab Treatment in Juvenile Idiopathic Arthritis: What Shall We Expect? A Pilot Study.
    Marino A; Orsini F; Pregnolato F; Cimaz R
    J Rheumatol; 2022 Jun; 49(6):654-656. PubMed ID: 35293329
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.